Encephalitis

CrossMark policy

Page Path

HOME
EDITORIAL POLICY
CrossMark policy

CrossMark is a multi-publisher initiative to provide a standard way for readers to locate the current version of a piece of content. By applying the CrossMark logo Korean Encephalitis and Neuroinflammation Society is committing to maintaining the content it publishes and to alerting readers to changes if and when they occur.

Clicking on the CrossMark logo will tell you the current status of a document and may also give you additional publication record information about the document.

MOST VIEWED MOST CITED

4,791	Neuroprotective effects of melatonin in neurodegenerative and autoimmune central nervous system diseases
5,398	Posttransplant lymphoproliferative disorder in a kidney transplant recipient: a case of Epstein-Barr virus-positive primary central nervous system lymphoma
3,434	Management of convulsive status epilepticus: recent updates
4,042	Lumbar puncture: considerations, procedure, and complications
1,530	COVID-19–related posterior reversible encephalopathy syndrome: insights from a clinical case

+more

Cited By 2	Management of convulsive status epilepticus: recent updates
Cited By 2	Protein biomarkers in multiple sclerosis
Cited By 1	Direct brain involvement of Takayasu arteritis treated with rituximab and infliximab: a case report
Cited By 1	Successful treatment with rituximab for central nervous system vasculitis caused by Epstein-Barr virus-associated lymphoproliferative disorder with immunoglobulin M gammopathy
Cited By 1	Chronic social stress during early development elicits unique behavioral changes in adulthood

+more

Editorial Office: 101, Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea
Tel: +82-2-2072-0629 Fax: +82-2-765-7920 E-mail: editor@encephalitisjournal.org